מכפיל P/S עתידי: Pulmonx Corp (LUNG)

Despite a heavy reliance on external equipment assemblers, Pulmonx Corporation remains resilient. The forward P/S metric reflects the current market valuation, with the value stabilizing at 1.40. Stability is driven by the recognized Zephyr systems and contracts with US clinics, while professional management effectively scales sales while maintaining strict control over operating expenses.
פילוחי נתונים אנליטיים מרוכזים עבור Pulmonx (LUNG)

To minimize fundamental risks, investors select assets with a stable ratio of market capitalization to projected revenue, which allows for an assessment of the premium paid for future growth. The trend of the expected P/S multiple reflects market confidence in the scaling of the Pulmonx Corporation clinic network, where a decrease in the indicator may signal an undervaluation of the expansion of innovative valves in the US market.